Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation

被引:44
作者
Fazzino, Fili [1 ]
Montes, Carol [2 ]
Urbina, Mary [1 ]
Carreira, Isabel [2 ]
Lima, Lucimey [1 ,2 ]
机构
[1] Inst Venezolano Invest Cient, Ctr Biofis & Bioquim, Lab Neuroquim, Caracas 1020A, Venezuela
[2] Hosp Ctr Salud Mental Este, Caracas, Venezuela
关键词
fluoxetine; lymphocyte proliferation; lymphocyte subpopulations; major depression; serotonin; serotonin transporter;
D O I
10.1016/j.jneuroim.2008.03.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Modifications of lymphocyte serotonergic system have been described in major depression. The aim of this study was to determine new possible changes of this system in depression. Twenty eight patients, free of drugs, diagnosed with major depression disorder by Structured Clinical Interview for Disorders of Axis 1, without medical illnesses, written consent, approved by Ethical Committees were included. Controls were 30 healthy subjects without family history of psychiatric disease. Blood monocytes were isolated with Ficoll/Hypaque, and lymphocytes by differential adhesion to plastic. Serotonin and 5-hydroxyindoleacetic acid determined by HPLC. Monocytes had higher serotonin concentrations than lymphocytes, and serotonin/5-hydroxyindoleacetic acid was lower in patients. Basal proliferation was elevated in depressed and not increased by Concanavalin A. Fluoxetine reduced basal proliferation more efficiently in patients, indicating activation of lymphocytes in depression. The number of cells expressing serotonin transporter was reduced in depressed. There were no differences in CD4+ (similar to 50%) or CD8+ (similar to 25%) lymphocytes between the groups, although CD8+ were lower in depressed, and greater number of them co-localized serotonin transporter than CD4+, which could be crucial for function in relation to serotonin and its receptors in immune cells. Lymphocytes were activated in this group of patients and fluoxetine reduced proliferation, probably being relevant for the psychopharmacological treatment of depression. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:173 / 180
页数:8
相关论文
共 40 条
[1]  
*AM PSYCH ASS, 2004, DSM 4 DIAGN STAT MAN
[2]  
ANESI A, 1994, FUNCT NEUROL, V9, P17
[3]  
Ayelli Edgar V, 1998, Acta Physiol Pharmacol Ther Latinoam, V48, P191
[4]   Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients [J].
Barkan, Tal ;
Peled, Avi ;
Modai, Ilan ;
Barak, Peretz ;
Weizman, Abraham ;
Rehavi, Moshe .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 (08) :572-579
[5]   AN INVENTORY FOR MEASURING DEPRESSION [J].
BECK, AT ;
ERBAUGH, J ;
WARD, CH ;
MOCK, J ;
MENDELSOHN, M .
ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) :561-&
[6]   IN-VITRO EFFECTS OF COCAINE, LIDOCAINE AND MONOAMINE UPTAKE INHIBITORS ON LYMPHOCYTE PROLIFERATIVE RESPONSES [J].
BERKELEY, MB ;
DAUSSIN, S ;
HERNANDEZ, MC ;
BAYER, BM .
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 1994, 16 (02) :165-178
[7]   Cutaneous marginal zone B-cell lymphoma in the setting of fluoxetine therapy:: a hypothesis regarding pathogenesis based on in vitro suppression of T-cell-proliferative response [J].
Breza, Thomas S., Jr. ;
Zheng, Pan ;
Porcu, Pierluigi ;
Magro, Cynthia M. .
JOURNAL OF CUTANEOUS PATHOLOGY, 2006, 33 (07) :522-528
[8]   Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop [J].
Cosentino, Marco ;
Fietta, Anna Maria ;
Ferrari, Marco ;
Rasini, Emanuela ;
Bombelli, Raffaella ;
Carcano, Elena ;
Saporiti, Federica ;
Meloni, Federica ;
Marino, Franca ;
Lecchini, Sergio .
BLOOD, 2007, 109 (02) :632-642
[9]   Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: Effects of fluoxetine [J].
Edgar, VA ;
Cremaschi, GA ;
Sterin-Borda, L ;
Genaro, AM .
BRAIN BEHAVIOR AND IMMUNITY, 2002, 16 (04) :333-350
[10]  
Edgar VA, 1999, EUR J PHARMACOL, V372, P65